BeOne Medicines (BEIGF) Operating Expenses (2015 - 2026)

BeOne Medicines (BEIGF) has reported Operating Expenses for 12 consecutive years, with $1.2 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Operating Expenses rose 13.43% year-over-year to $1.2 billion in Q2 2026; TTM through Jun 2026 was $4.5 billion, a 13.07% increase from a year earlier, with the FY2025 full-year figure at $4.2 billion, up 11.71% from the prior year.
• Operating Expenses was $1.2 billion for Q2 2026 at BeOne Medicines, up from $1.1 billion in the prior quarter.
• Over five years, Operating Expenses peaked at $1.2 billion in Q2 2026 and troughed at $562.2 million in Q4 2022.
• A 5-year average of $917.7 million and a median of $905.3 million in 2023 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses decreased 9.43% in 2022 and surged 62.27% in 2023, its largest moves.
• Over 5 years, Operating Expenses stood at $562.2 million in 2022, then surged by 62.27% to $912.4 million in 2023, then gained by 14.72% to $1.0 billion in 2024, then advanced by 11.85% to $1.2 billion in 2025, then climbed by 2.97% to $1.2 billion in 2026.
• The last three Operating Expenses figures came in at $1.2 billion (Q2 2026), $1.1 billion (Q1 2026), and $1.2 billion (Q4 2025), per Business Quant data.